[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@KontraInvest Kontra

Kontra posts on X about $nvo, emerging markets, math, $aipa the most. They currently have XXXXX followers and XX posts still getting attention that total XXX engagements in the last XX hours.

Engagements: XXX #

• X Week XXXXX +75%
• X Month XXXXXX -XX%
• X Months XXXXXXX +299%
• X Year XXXXXXX +240%

Mentions: X #

• X Week XX +11%
• X Month XX -XX%
• X Months XXX +20%
• X Year XXX +25%

Followers: XXXXX #

• X Week XXXXX +0.39%
• X Month XXXXX +2.30%
• X Months XXXXX +13%
• X Year XXXXX +17%

CreatorRank: XXXXXXXXX #

Social Influence

Social category influence finance XX% stocks XX% currencies XX%

Social topic influence $nvo 10%, emerging markets 10%, math 10%, $aipa 10%, $teva 10%, if you 10%, money 10%, debt 10%, deflation 10%, realtime XX%

Top accounts mentioned or mentioned by @preseidentmusk @futileturtle

Top assets mentioned Novo-Nordisk (NVO) Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA)

Top Social Posts

Top posts by engagements in the last XX hours

"The market is pricing a funeral for a duopoly king $NVO Everyone is chasing Lilly at 35x earnings while leaving Novo Nordisk for dead at 13x. I get it. The 2026 narrative is ugly. We have patent cliffs in emerging markets "Most-Favored-Nation" pricing cuts in the US and a projected EPS drop of 7%. The chart looks like a crime scene. But lets look at the implied math. At XXX DKK the market is pricing in a -XXXX% annual revenue declinefor the next five years. For a company with a functional duopoly in the biggest health trend of the century That is capitulation math. Im not ignoring the"
X Link 2025-12-07T20:48Z 1814 followers, 23K engagements

"New article up on the blog $AI.PA - link in reply"
X Link 2025-07-23T23:23Z 1813 followers, XXX engagements

"The market loves a good "dead money" narrative. Its lazy. Its easy. And in the case of $TEVA its completely wrong. Most people still think Teva is a zombie generic co. saddled with debt fighting deflation. Theyre looking in the rearview mirror. If you look at the windshield you see a massive repricing event happening in real-time. Here is the setup nobody is talking about: The Catalyst Just Hit: Olanzapine NDA submitted. This isn't a pipe dream. Its a potential $2B franchise entering an uncontested market. Zero competition. No black box. This is the "fiction to nonfiction" moment. The Margin"
X Link 2025-12-12T08:54Z 1814 followers, XXX engagements